Feb 5, 2025 · Pharmaceutical giant Novo Nordisk has set goals to change its nature impact from negative to positive by 2045 through new innovations and optimisations

1 day ago · On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial, which determined that the Company's CagriSema product had achieved a weight loss average …

Oct 2, 2024 · Novo Nordisk, a leading healthcare company specializing in treating diabetes, chronic diseases, and endocrine disorders, upholds a set of core values that guide its …

At Novo Nordisk, we continuously optimise our products and processes to ensure treatments for people living with serious chronic diseases with the lowest possible impact on the …

5 days ago · Novo Nordisk has unveiled an ambitious plan to become nature-positive by 2045 and halt nature loss in its value chain by 2033, reflecting a growing recognition that preserving …

Feb 5, 2025 · Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Feb 5, 2025 · Shares of Novo Nordisk (NVO-2.90%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day.

6 days ago · The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from …

6 days ago · Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.

Feb 5, 2025 · Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.